Anomalies of Dense Platelet Granules

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

166 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-09

Study Completion Date

2023-02-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to know the overall prevalence of granular deficits and their breakdown by type (anomaly of number, content or secretion) in a population of patients with hemorrhagic symptomatology after exclusion of other known causes.

This study consists also to evaluate the association between the presence of a deficit in dense granules and (1) the intensity of the hemorrhagic phenotype (hemorrhagic score) (2) the nature of hemorrhages (post-operative, spontaneous, atypical...)

-Evaluate the association between the type of deficit in dense granules and (1) the intensity of the hemorrhagic phenotype (hemorrhagic score) (2) the nature of hemorrhages (post-operative, spontaneous, atypical...)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Constitutional Platelet Disease

NCT04419987

Blood Platelet Disease

UNKNOWN NA

Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.

NCT04070599

Immune Thrombocytopenic Purpura Autoimmune Thrombocytopenia Thrombopenia

COMPLETED PHASE3

Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura

NCT04056507

Immune Thrombocytopenic Purpura Splenectomy; Status

COMPLETED

Bleeding Prediction in Thrombocytopenia

NCT02306044

Thrombocytopenia

COMPLETED

Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia

NCT07182760

Primary Immune Thrombocytopenic Purpura Amegakaryocytic Aplasia Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia) +2 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be recruited during the exploration visit (v0) or the confirmation/typing visit (v1) according to their follow-up.

* Exploration visit (v0): inclusion of patients without prior platelet exploration, and study of their dense platelet granules.
* Confirmation/typing visit (v1): verification of the persistence of anomalies detected in patients with an abnormality identified during v0 (no later than 6 months after v0) and in patients for whom a dense granules anomaly has already been identified during their standard management prior to the start of the study. Completion of complementary examinations to complement the typing of the granular anomaly and molecular analysis for family cases

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spontaneous Induced Unexplained Haemorrhagic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children and adults with unexplained hemorrhagic syndrome

Patients with spontaneous or induced hemorrhagic manifestations who are present for a consultation to investigate a thrombopathy or during follow-up consultations as part of their usual care.

Haemostasis consultation

Intervention Type OTHER

Haemostasis consultation

Standard management of patients suspected of thrombopathy

Intervention Type BIOLOGICAL

Standard management of patients suspected of thrombopathy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Haemostasis consultation

Intervention Type OTHER

Standard management of patients suspected of thrombopathy

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult or child patient ≥ 2 years
* Having a hemorrhagic score ISTH \> 3 for men, \> 5 for women and \> 2 for children.
* With no abnormal coagulation (defined by normal TP and TCK or activity ≥ 50% of FII, FV, FVII, FX, FVIII, FIX, FXI)
* no deficiency of Willebrand factor (defined by a cofactor activity with Ristoctin (VWF: RCo \< 50%))
* no a known major thrombocytopenia/thrombopathy linked to a deficiency of one of the major platelet receptors
* Information of the patient and/or his legal representative present

Exclusion Criteria

* Inability or refusal of compliance with research requirements
* Thrombocytopenia \< 100 G/L
* Treatments interfering with platelet functions within 10 days prior to inclusion
* Malignant hemopathy

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No